drugset / Trial / NCT01895543

Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation

NCT01895543

Phase 3 Completed 411 enrolled Ferring Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Safety and Tolerability Extension Trial for Patients with Chronic Idiopathic Constipation (CIC)

Timeline

Start
2013-09
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Elobixibat Small molecule 5 mg
Subject Elobixibat Small molecule 10 mg

Indications